美因基因(06667.HK)擬全球發售1196.18萬股 引入邁克生物等基石
格隆匯6月10日丨美因基因(06667.HK)發佈公吿，公司擬全球發售1196.18萬股股份，其中香港發售股份119.62萬股，國際發售股份1076.56萬股，另有15%超額配股權；2022年6月10日至6月15日招股，預期定價日為6月15日；發售價為每股發售股份18.00-22.00港元，每手買賣單位200股，入場費約4444港元；中信建投國際為獨家保薦人；預期股份將於2022年6月22日於聯交所主板掛牌上市。
公司是中國領先的基因檢測平台公司，專注於消費級基因檢測及癌症篩查服務。截至2021年12月31日，自2016年成立以來，公司進行了超過1200萬次基因檢測，2021年平均每月進行逾24.6萬次檢測。根據弗若斯特沙利文的資料，按累計已進行檢測量計，公司為中國最大的消費級基因檢測平台。同時，根據弗若斯特沙利文的資料，按2020年已進行檢測量計，公司是中國規模最大的癌症篩查基因檢測平台。
公司已訂立基石投資協議，據此，基石投資者已同意在若干條件規限下按發售價認購或促使其指定實體(包括合格境內機構投資者)認購若干數目的發售股份。基於發售價每股發售股份20港元(即本招股章程所載發售價範圍的中位數)，基石投資者將認購的股份總數為893.48萬股。基石投資者包括南昌金融控股有限公司、南昌工控園區股權投資合夥企業(有限合夥)及邁克生物(300463.SZ)。
假設超額配股權未獲行使及假設發售價為每股股份20港元，公司估計將自全球發售收取所得款項淨額合共約1.901億港元。公司現時擬將全球發售所得款項淨額約30%用於公司的消費級基因檢測及癌症篩查服務及產品的銷售、營銷及商業化；約25%將投資於研發公司的服務及產品；約20%將用於增加或擴大公司的檢測能力及產能；約15%將用於通過投資或收購具吸引力的技術或檢測相關公司，為公司在整個行業價值鏈的擴張提供資金；及約10%預期將用作營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
